Mauritania vs Sweden: Access to anti-retroviral drugs, male
Mauritania
97.0%
in 2024
Sweden
95.0%
in 2022
Mauritania rank
2nd
Sweden rank
4th
Access to anti-retroviral drugs, male over time
- Mauritania
- Sweden
How they compare
Mauritania currently reports 97.0% against 95.0% in Sweden, a difference of 2.0%.
Across all 23 years both countries report, Sweden has been ahead every year.
Mauritania ranks 2nd and Sweden ranks 4th of 141 countries.
Sweden has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Mauritania | Sweden | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 3.7% | 53.7% | 50.0% | Sweden |
| 2010s | 33.4% | 92.5% | 59.1% | Sweden |
| 2020s | 70.3% | 95.3% | 25.0% | Sweden |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Mauritania or Sweden?
- Mauritania, at 97.0% against 95.0% in Sweden as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Mauritania and Sweden?
- 2.0%, with Mauritania ahead.
- How many years of comparable data are there for Mauritania and Sweden?
- 23 years are reported by both, from 2000 to 2022.
- How do Mauritania and Sweden rank globally for access to anti-retroviral drugs, male?
- Mauritania ranks 2nd and Sweden ranks 4th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.